Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting.

Wirth M, Fossati N, Albers P, Bangma C, Brausi M, Comperat E, Faithfull S, Gillessen S, Jereczek-Fossa BA, Mastris K, Mottet N, Müller SC, Pieters B, Ribal MJ, Sangar V, Schoots IG, Smelov V, Travado L, Valdagni R, Wesselmann S, Wiegel T, van Poppel H.

Eur Urol. 2019 Feb 21. pii: S0302-2838(19)30077-6. doi: 10.1016/j.eururo.2019.01.033. [Epub ahead of print]

PMID:
30799188
2.

Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.

van Luijtelaar A, Greenwood BM, Ahmed HU, Barqawi AB, Barret E, Bomers JGR, Brausi MA, Choyke PL, Cooperberg MR, Eggener S, Feller JF, Frauscher F, George AK, Hindley RG, Jenniskens SFM, Klotz L, Kovacs G, Lindner U, Loeb S, Margolis DJ, Marks LS, May S, Mcclure TD, Montironi R, Nour SG, Oto A, Polascik TJ, Rastinehad AR, De Reyke TM, Reijnen JS, de la Rosette JJMCH, Sedelaar JPM, Sperling DS, Walser EM, Ward JF, Villers A, Ghai S, Fütterer JJ.

World J Urol. 2019 Jan 22. doi: 10.1007/s00345-019-02636-7. [Epub ahead of print]

3.

Systematic Review on the Utilization of Maintenance Intravesical Chemotherapy in the Management of Non-muscle-invasive Bladder Cancer.

Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J, Brausi M, Black PC, Williams SB.

Eur Urol Focus. 2018 Jul;4(4):512-521. doi: 10.1016/j.euf.2018.08.019. Epub 2018 Sep 3.

PMID:
30190111
4.

Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer.

Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM.

World J Urol. 2019 Jan;37(1):3-13. doi: 10.1007/s00345-018-2436-y. Epub 2018 Aug 13. Review.

PMID:
30105454
5.

Multidisciplinary teams for the proper management of patients with genitourinary tumors: When topics set scientific societies' agenda.

Magnani T, Bracarda S, D'Angelillo RM, Artibani W, Barni S, Beretta G, Brausi M, Caffo O, Corvò R, Gallucci M, Gunelli R, Mirone V, Novara G, Pinto C, Russi E, Santoni R, Tomirotti M, Volpe A, Conti G, Valdagni R.

Tumori. 2019 Apr;105(2):161-167. doi: 10.1177/0300891618784789. Epub 2018 Jul 5.

PMID:
29974825
6.

Impact of Metabolic Diseases, Drugs, and Dietary Factors on Prostate Cancer Risk, Recurrence, and Survival: A Systematic Review by the European Association of Urology Section of Oncological Urology.

Campi R, Brookman-May SD, Subiela Henríquez JD, Akdoğan B, Brausi M, Klatte T, Langenhuijsen JF, Linares-Espinos E, Marszalek M, Roupret M, Stief CG, Volpe A, Minervini A, Rodriguez-Faba O.

Eur Urol Focus. 2018 Apr 13. pii: S2405-4569(18)30090-7. doi: 10.1016/j.euf.2018.04.001. [Epub ahead of print] Review.

PMID:
29661588
7.

Latest Evidence on the Impact of Smoking, Sports, and Sexual Activity as Modifiable Lifestyle Risk Factors for Prostate Cancer Incidence, Recurrence, and Progression: A Systematic Review of the Literature by the European Association of Urology Section of Oncological Urology (ESOU).

Brookman-May SD, Campi R, Henríquez JDS, Klatte T, Langenhuijsen JF, Brausi M, Linares-Espinós E, Volpe A, Marszalek M, Akdogan B, Roll C, Stief CG, Rodriguez-Faba O, Minervini A.

Eur Urol Focus. 2018 Mar 22. pii: S2405-4569(18)30069-5. doi: 10.1016/j.euf.2018.02.007. [Epub ahead of print] Review.

PMID:
29576530
8.

Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder.

Vetterlein MW, Roschinski J, Gild P, Marks P, Soave A, Doh O, Isbarn H, Höppner W, Wagner W, Shariat SF, Brausi M, Büscheck F, Sauter G, Fisch M, Rink M.

Transl Androl Urol. 2017 Dec;6(6):1018-1026. doi: 10.21037/tau.2017.11.10.

9.

Re: Robot-assisted Laparoscopic Prostatectomy Versus Open Radical Retropubic Prostatectomy: Early Outcomes from a Randomised Controlled Phase 3 Study.

Brausi M.

Eur Urol. 2017 Nov;72(5):856-857. doi: 10.1016/j.eururo.2017.07.029. Epub 2017 Aug 26. No abstract available.

PMID:
28851579
10.

Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.

Faba OR, Brookman-May SD, Linares E, Breda A, Pisano F, Subiela JD, Sanguedolce F, Brausi M, Palou J.

World J Urol. 2017 Dec;35(12):1807-1816. doi: 10.1007/s00345-017-2072-y. Epub 2017 Jul 12. Review.

PMID:
28702843
11.

BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.

Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, Buckley R, Persad R, Palou J, Soloway M, Witjes JA.

Nat Rev Urol. 2017 Apr;14(4):244-255. doi: 10.1038/nrurol.2017.16. Epub 2017 Feb 21. Review.

PMID:
28248951
12.

Role of cigarette smoking in urological malignancies and clinical interventions for smoking cessation.

Sosnowski R, Bjurlin MA, Verze P, De Nunzio C, Shariat SF, Brausi M, Donin NM.

Cent European J Urol. 2016;69(4):366-369. doi: 10.5173/ceju.2016.883. Epub 2016 Nov 30.

13.

Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction.

Redrow GP, Guo CC, Brausi MA, Coleman JA, Fernandez MI, Kassouf W, Keeley FX Jr, Margulis V, Raman JD, Roupret M, Shariat SF, Spiess PE, Thalmann GN, Matin SF.

J Urol. 2017 Feb;197(2):287-295. doi: 10.1016/j.juro.2016.03.194. Epub 2016 Sep 21. Review.

PMID:
27664578
14.

Prevalence of Cardiovascular Disease and Osteoporosis During Androgen Deprivation Therapy Prescription Discordant to EAU Guidelines: Results From a Multicenter, Cross-sectional Analysis From the CHOsIng Treatment for Prostate canCEr (CHOICE) Study.

Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P, Trippa F, Zattoni F, Porena M, Mirone V, Serni S, Del Nero A, Lay G, Ricardi U, Rocco F, Terrone C, Pagliarulo A, Ludovico G, Vespasiani G, Brausi M, Simeone C, Novella G, Carmignani G, Leonardi R, Pinnarò P, De Paula U, Corvò R, Tenaglia R, Siracusano S, Mantini G, Gontero P, Savoca G, Ficarra V; L. U. N. A. Foundation and Società Italiana d'Urologia).

Urology. 2016 Oct;96:165-170. doi: 10.1016/j.urology.2016.06.024. Epub 2016 Jul 8.

PMID:
27402374
15.

The treatment of Ta-T1 bladder cancer in the era of worldwide BCG shortage.

Brausi M, Morselli S.

Minerva Urol Nefrol. 2016 Apr;68(2):192-3. Epub 2016 Mar 16. No abstract available.

PMID:
26982374
16.
17.

Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.

Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ.

World J Urol. 2016 Oct;34(10):1373-82. doi: 10.1007/s00345-016-1782-x. Epub 2016 Feb 18. Review.

18.

Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group.

Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA.

J Clin Oncol. 2016 Jun 1;34(16):1935-44. doi: 10.1200/JCO.2015.64.4070. Epub 2016 Jan 25. Review.

19.

Patterns of prescription and adherence to European Association of Urology guidelines on androgen deprivation therapy in prostate cancer: an Italian multicentre cross-sectional analysis from the Choosing Treatment for Prostate Cancer (CHOICE) study.

Morgia G, Russo GI, Tubaro A, Bortolus R, Randone D, Gabriele P, Trippa F, Zattoni F, Porena M, Mirone V, Serni S, Del Nero A, Lay G, Ricardi U, Rocco F, Terrone C, Pagliarulo A, Ludovico G, Vespasiani G, Brausi M, Simeone C, Novella G, Carmignani G, Leonardi R, Pinnarò P, De Paula U, Corvò R, Tenaglia R, Siracusano S, Mantini G, Gontero P, Savoca G, Ficarra V; (Members of the LUNA Foundation, Società Italiana d'Urologia).

BJU Int. 2016 Jun;117(6):867-73. doi: 10.1111/bju.13307. Epub 2015 Sep 23.

20.

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.

Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, Kirkels WJ, Silva FC, Oosterlinck W, Prescott S, Kirkali Z, Powell PH, de Reijke TM, Turkeri L, Collette S, Oddens J.

Eur Urol. 2016 Jan;69(1):60-9. doi: 10.1016/j.eururo.2015.06.045. Epub 2015 Jul 23.

PMID:
26210894
21.

Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology.

Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A.

Crit Rev Oncol Hematol. 2015 Aug;95(2):133-43. doi: 10.1016/j.critrevonc.2015.05.014. Epub 2015 Jun 5. Review.

PMID:
26092320
22.

Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives.

Bach T, Muschter R, Herrmann TR, Knoll T, Scoffone CM, Laguna MP, Skolarikos A, Rischmann P, Janetschek G, De la Rosette JJ, Nagele U, Malavaud B, Breda A, Palou J, Bachmann A, Frede T, Geavlete P, Liatsikos E, Jichlinski P, Schwaibold HE, Chlosta P, Martov AG, Lapini A, Schmidbauer J, Djavan B, Stenzl A, Brausi M, Rassweiler JJ.

BJU Int. 2015 Jan;115(1):14-23. Epub 2014 Jul 14. Review.

PMID:
25646531
23.

Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project.

Muller BG, van den Bos W, Brausi M, Fütterer JJ, Ghai S, Pinto PA, Popeneciu IV, de Reijke TM, Robertson C, de la Rosette JJ, Scionti S, Turkbey B, Wijkstra H, Ukimura O, Polascik TJ.

World J Urol. 2015 Oct;33(10):1503-9. doi: 10.1007/s00345-014-1475-2. Epub 2015 Jan 6. Review.

PMID:
25559111
24.

World Urologic Oncology Federation Bladder Cancer Prevention Program: a global initiative.

Klotz L, Brausi MA.

Urol Oncol. 2015 Jan;33(1):25-9. doi: 10.1016/j.urolonc.2014.07.017. Review.

PMID:
25528636
25.

Concordance and clinical significance of uncommon variants of bladder urothelial carcinoma in transurethral resection and radical cystectomy specimens.

Cai T, Tiscione D, Verze P, Pomara G, Racioppi M, Nesi G, Barbareschi M, Brausi M, Gacci M, Luciani LG, Liguori G, Gontero P, Campodonico F, Simonato A, Boddi V, Di Stasi SM, Colombo R, Serretta V, Carmignani G, Malossini G, Altieri V, Carini M, Terrone C, Bassi P, Montorsi F, Ficarra V, Selli C, Mirone V, Bartoletti R.

Urology. 2014 Nov;84(5):1141-6. doi: 10.1016/j.urology.2014.06.032. Epub 2014 Sep 18.

PMID:
25239253
26.

The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcome.

Racioppi M, Salmaso L, Brombin C, Arboretti R, D'Agostino D, Colombo R, Serretta V, Brausi M, Casetta G, Gontero P, Hurle R, Tenaglia R, Altieri V, Bartoletti R, Maffezzini M, Siracusano S, Morgia G, Bassi PF.

Urol Int. 2015;94(3):262-9. doi: 10.1159/000365292. Epub 2014 Aug 27.

PMID:
25171377
27.

The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.

Oddens JR, Sylvester RJ, Brausi MA, Kirkels WJ, van de Beek C, van Andel G, de Reijke TM, Prescott S, Witjes JA, Oosterlinck W.

Eur Urol. 2014 Oct;66(4):694-701. doi: 10.1016/j.eururo.2014.05.033. Epub 2014 Jun 16.

PMID:
24948466
28.

Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer.

Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J.

J Urol. 2014 Aug;192(2):305-15. doi: 10.1016/j.juro.2014.02.2573. Epub 2014 Mar 25. Review.

29.

EAU policy on live surgery events.

Artibani W, Ficarra V, Challacombe BJ, Abbou CC, Bedke J, Boscolo-Berto R, Brausi M, de la Rosette JJ, Deger S, Denis L, Guazzoni G, Guillonneau B, Heesakkers JP, Jacqmin D, Knoll T, Martínez-Piñeiro L, Montorsi F, Mottrie A, Piechaud PT, Rane A, Rassweiler J, Stenzl A, Van Moorselaar J, Van Velthoven RF, van Poppel H, Wirth M, Abrahamsson PA, Parsons KF.

Eur Urol. 2014 Jul;66(1):87-97. doi: 10.1016/j.eururo.2014.01.028. Epub 2014 Jan 30. Review.

PMID:
24560818
30.

Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project.

Muller BG, van den Bos W, Brausi M, Cornud F, Gontero P, Kirkham A, Pinto PA, Polascik TJ, Rastinehad AR, de Reijke TM, de la Rosette JJ, Ukimura O, Villers A, Walz J, Wijkstra H, Marberger M.

BJU Int. 2014 Nov;114(5):698-707. doi: 10.1111/bju.12548. Epub 2014 Aug 16.

31.

Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition.

Lamm D, Persad R, Brausi M, Buckley R, Witjes JA, Palou J, Böhle A, Kamat AM, Colombel M, Soloway M.

J Urol. 2014 Jan;191(1):20-7. doi: 10.1016/j.juro.2013.07.102. Epub 2013 Aug 22. Review.

PMID:
23973937
32.

Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.

Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S, Collette S, Oosterlinck W.

Eur Urol. 2014 Jan;65(1):69-76. doi: 10.1016/j.eururo.2013.07.021. Epub 2013 Jul 24.

PMID:
23910233
33.
34.

Lymphadenectomy for bladder cancer at the time of radical cystectomy.

Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, Shariat SF, Bochner BH.

Eur Urol. 2013 Aug;64(2):266-76. doi: 10.1016/j.eururo.2013.04.036. Epub 2013 Apr 29. Review.

PMID:
23648149
35.

Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.

Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, Tammela TL, Calais da Silva F.

Eur Urol. 2013 Nov;64(5):722-30. doi: 10.1016/j.eururo.2013.04.020. Epub 2013 Apr 19. Review.

PMID:
23628492
36.

Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.

Lamm D, Brausi M, O'Donnell MA, Witjes JA.

Urol Oncol. 2014 Jan;32(1):35.e21-30. doi: 10.1016/j.urolonc.2013.02.010. Epub 2013 Apr 28. Review.

PMID:
23628309
37.

Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).

Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, Böhle A.

BJU Int. 2013 Oct;112(6):742-50. doi: 10.1111/bju.12012. Epub 2013 Mar 1.

38.

Management of high-risk non-muscle invasive bladder cancer.

Brausi M, Olaru V.

Minerva Urol Nefrol. 2012 Dec;64(4):255-60. Review.

PMID:
23288212
39.

Collateral activity of immunotherapy with bacillus Calmette-Guérin for the treatment of non-muscle-invasive transitional cell carcinoma of the bladder: new insights.

Brausi M, Siracusano S.

Eur Urol. 2013 May;63(5):836-7; discussion 837-8. doi: 10.1016/j.eururo.2012.11.033. Epub 2012 Nov 21. No abstract available.

PMID:
23219084
40.

Primary prevention and early detection of bladder cancer: two main goals for urologists.

Brausi MA.

Eur Urol. 2013 Feb;63(2):242-3. doi: 10.1016/j.eururo.2012.10.038. Epub 2012 Oct 26. No abstract available.

PMID:
23141936
41.

Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Hoeltl W, Turkeri L, Marreaud S, Collette S, Oosterlinck W.

Eur Urol. 2013 Mar;63(3):462-72. doi: 10.1016/j.eururo.2012.10.039. Epub 2012 Nov 2.

PMID:
23141049
42.

ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder.

Burger M, Oosterlinck W, Konety B, Chang S, Gudjonsson S, Pruthi R, Soloway M, Solsona E, Sved P, Babjuk M, Brausi MA, Cheng C, Comperat E, Dinney C, Otto W, Shah J, Thürof J, Witjes JA; International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012.

Eur Urol. 2013 Jan;63(1):36-44. doi: 10.1016/j.eururo.2012.08.061. Epub 2012 Sep 5. Review.

PMID:
22981672
43.

Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.

Yates DR, Brausi MA, Catto JW, Dalbagni G, Rouprêt M, Shariat SF, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J.

Eur Urol. 2012 Dec;62(6):1088-96. doi: 10.1016/j.eururo.2012.08.055. Epub 2012 Sep 3. Review.

PMID:
22959049
44.

Anticancer activity of green tea polyphenols in prostate gland.

Davalli P, Rizzi F, Caporali A, Pellacani D, Davoli S, Bettuzzi S, Brausi M, D'Arca D.

Oxid Med Cell Longev. 2012;2012:984219. doi: 10.1155/2012/984219. Epub 2012 May 15. Review.

45.
46.

Words of wisdom. Re: Long-term follow-up of T1 high-grade bladder cancer after intravesical Bacille Calmette-Guerin (BCG) treatment.

Brausi MA.

Eur Urol. 2012 Apr;61(4):845-6. doi: 10.1016/j.eururo.2012.01.031. No abstract available.

PMID:
22373879
47.

The future of urology.

Abrams P, Brausi M, Buntrock S, Ebert T, Hashim H, Tiselius HG, Wyndaele JJ.

Eur Urol. 2012 Mar;61(3):534-40. doi: 10.1016/j.eururo.2011.11.005. Epub 2011 Nov 12.

PMID:
22137602
48.

Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study.

Brausi MA, Gontero P, Altieri V, Colombo R, Conti I, Bono AV.

Urol Int. 2011;87(4):470-4. doi: 10.1159/000331727. Epub 2011 Nov 11.

PMID:
22086229
49.

A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.

Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Böhle A.

J Urol. 2011 Dec;186(6):2158-67. doi: 10.1016/j.juro.2011.07.076. Epub 2011 Oct 19. Review.

PMID:
22014799
50.

Measuring and improving the quality of transurethral resection for bladder tumour (TURBT).

Mostafid H, Brausi M.

BJU Int. 2012 Jun;109(11):1579-82. doi: 10.1111/j.1464-410X.2011.10638.x. Epub 2011 Oct 12. No abstract available.

Supplemental Content

Loading ...
Support Center